3results about How to "Reduce proteinuria" patented technology

This invention discloses the application of a PDLIM2 gene overexpression viral vector in the preparation of drugs for treating podocyte disease, wherein the nucleotide sequence of the PDLIM2 gene is shown in SEQ ID NO:1. This invention is the first to discover and verify the core role of the PDLIM2 gene in podocyte protection, confirming its significant downregulation in DKD and FSGS disease models, and demonstrating through functional experiments that PDLIM2 overexpression can effectively stabilize the podocyte cytoskeleton, inhibit apoptosis, and reduce proteinuria, thus establishing it as a key target gene for the treatment of podocyte disease. This invention is the first to intervene at the gene level in the core link of podocyte damage—cytoskeleton stability. By specifically upregulating the expression of PDLIM2 in podocytes, it directly enhances their intrinsic cytoskeleton support and anti-damage ability, achieving a fundamental shift in treatment strategy from "symptomatic support" to "causal repair."

The invention discloses application of a PDLIM2 gene overexpression virus vector in preparation of a medicine for treating podocytosis. The nucleotide sequence of a PDLIM2 gene is as shown in SEQ ID NO: 1. The core effect of the PDLIM2 gene in podocytosis protection is found and verified for the first time, it is confirmed that the expression of the PDLIM2 gene in DKD and FSGS disease models is remarkably reduced, and functional experiments prove that the overexpression of the PDLIM2 can effectively stabilize podocytoskeleton, inhibit apoptosis and relieve proteinuria, so that the PDLIM2 gene is determined as a key target gene for treating podocytosis. According to the invention, the stability of the cytoskeleton, which is a core link of podocyte injury, is intervened from the gene level for the first time. The expression of the PDLIM2 in the podocyte is specifically up-regulated, so that the internal cytoskeleton support and damage resistance of the podocyte are directly enhanced, and the fundamental treatment strategy conversion from symptomatic support to cause repair is realized.

The invention relates to the technical field of traditional Chinese medicine preparations, and particularly discloses a traditional Chinese medicine composition for treating diabetic nephropathy and application thereof. The traditional Chinese medicine composition is prepared from the following ten medicinal materials according to a specific ratio: radix rehmanniae recen, astragalus membranaceus, golden cypress, coptis chinensis, gastrodia elata, cicada slough, salvia miltiorrhiza, chinaroot greenbrier, rosa laevigata michx and motherwort. Systematic animal experiments and clinical researches prove that the Zuogui blood-glucose-reducing kidney-pleasing formula can effectively reduce fasting blood-glucose of diabetic nephropathy model mice, improve lipid metabolism disorder, remarkably reduce the levels of urea nitrogen, creatinine and uric acid and the ratio of urine protein to creatinine, and can be used for treating diabetic nephropathy by inhibiting expression of fibrosis-related factors such as TGF-beta and alpha-SMA. The renal fibrosis process is delayed. Compared with the prior art, the pharmaceutical composition provided by the invention has remarkable advantages in the aspects of improving renal functions, inhibiting renal tissue fibrosis and delaying the development of diabetic nephropathy.